Extracellular Vesicles in Brain Tumors and Neurodegenerative Diseases

Extracellular vesicles (EVs) can be classified into apoptotic bodies, microvesicles (MVs), and exosomes, based on their origin or size. Exosomes are the smallest and best characterized vesicles which derived from the endosomal system. These vesicles are released from many different cell types includ...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in molecular neuroscience Vol. 10; p. 276
Main Authors Ciregia, Federica, Urbani, Andrea, Palmisano, Giuseppe
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Research Foundation 31.08.2017
Frontiers Media S.A
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Extracellular vesicles (EVs) can be classified into apoptotic bodies, microvesicles (MVs), and exosomes, based on their origin or size. Exosomes are the smallest and best characterized vesicles which derived from the endosomal system. These vesicles are released from many different cell types including neuronal cells and their functions in the nervous system are investigated. They have been proposed as novel means for intercellular communication, which takes part not only to the normal neuronal physiology but also to the transmission of pathogenic proteins. Indeed, exosomes are fundamental to assemble and transport proteins during development, but they can also transfer neurotoxic misfolded proteins in pathogenesis. The present review will focus on their roles in neurological diseases, specifically brain tumors, such as glioblastoma (GBM), neuroblastoma (NB), medulloblastoma (MB), and metastatic brain tumors and chronic neurodegenerative diseases, such as Alzheimer, Parkinson, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Huntington, and Prion diseseases highlighting their involvement in spreading neurotoxicity, in therapeutics, and in pathogenesis.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Claudia Verderio, Consiglio Nazionale Delle Ricerche (CNR), Italy; Na Tosha N. Gatson, Geisinger Health System, United States; Diego Albani, Istituto Di Ricerche Farmacologiche Mario Negri, Italy
Edited by: Andrei Surguchov, Kansas University of Medical Center Research Institute, United States
ISSN:1662-5099
1662-5099
DOI:10.3389/fnmol.2017.00276